I-Mab reported positive Phase 1b study results for givastomig in metastatic gastric cancers, highlighting significant efficacy and a favorable safety profile. I-Mab has announced positive results from ...
Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback